Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N-0310 Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, N-0316 Oslo, Norway.
Institute of Cytology, Medical University of Graz, A-8036 Graz, Austria.
Hum Pathol. 2018 Sep;79:122-126. doi: 10.1016/j.humpath.2018.05.012. Epub 2018 May 24.
The aim of this study was to analyze the diagnostic role of BAP1 in effusion cytology. Effusions (n = 258), consisting of 53 malignant mesotheliomas and 205 other cancers, the majority carcinomas (62 breast, 60 ovarian, 31 lung, 51 carcinomas of other origin, 1 melanoma), were analyzed for BAP1 expression using immunohistochemistry. BAP1 was lost in 46 (87%) mesotheliomas compared with 4 (2%) of 205 other cancers (P < .001), resulting in sensitivity and specificity of 87% and 98%, respectively. There was no significant difference between peritoneal (n = 14) and pleural (n = 39) mesotheliomas. The 4 carcinomas with loss of BAP1 included 1 ovarian, 1 breast, 1 uterine cervical, and 1 gastric carcinoma. The present study supports the role of BAP1 as a highly sensitive and specific marker for malignant mesothelioma in serous effusions and argues for inclusion of this test in all specimens in which this diagnosis is considered.
本研究旨在分析 BAP1 在胸腔积液细胞学诊断中的作用。共分析了 258 例胸腔积液，其中 53 例为恶性间皮瘤，205 例为其他癌症，多数为腺癌（62 例乳腺癌、60 例卵巢癌、31 例肺癌、51 例其他来源的癌、1 例黑色素瘤）。采用免疫组织化学法检测 BAP1 的表达。与 205 例其他癌症（4 例，2%）相比，46 例（87%）间皮瘤中 BAP1 缺失（P <.001），敏感性和特异性分别为 87%和 98%。腹膜性（n=14）和胸膜性（n=39）间皮瘤之间无显著差异。BAP1 缺失的 4 例癌包括 1 例卵巢癌、1 例乳腺癌、1 例宫颈癌和 1 例胃癌。本研究支持 BAP1 作为浆膜腔积液中恶性间皮瘤高度敏感和特异的标志物，主张在考虑该诊断的所有标本中均进行该检测。
